Cancer Risk Is Significantly Higher for Adults Who Never Married, Large Study Finds
oncodaily - Analysis of 4 million cases finds higher cancer rates across most types, especially for preventable cancers. Adults who have never been married face a significantly higher risk of developing cancer […]
AI Summary: A large observational analysis found that adults who never married have a significantly higher cancer risk compared with married peers, after adjusting for common confounders. Researchers highlight social, behavioral and access‑to‑care factors as possible contributors, suggesting that relationship status may serve as a marker for targeted prevention and support interventions.
- Lifestyle, sleep and fertility linked to cancer risk (3)
- Never-married adults face significantly higher cancer risk (3)
- Place, education and loneliness drive cancer disparities (3)
Lifestyle, sleep and fertility linked to cancer risk
Never-married adults face significantly higher cancer risk
Place, education and loneliness drive cancer disparities
UCLA Researchers Develop Low-Cost Blood Test to Detect Multiple Cancers And Other Diseases From a Single Sample
oncodaily - The new method analyzes genome-wide methylation of DNA circulating in the bloodstream to detect liver, lung, ovarian and stomach cancers, as well as several non-cancer conditions. UCLA scientists have developed […]
AI Summary: Researchers at UCLA introduced a low-cost blood test capable of detecting multiple cancers and other diseases from a single sample, promising broader screening reach and earlier detection. If validated at scale, the technology could lower barriers to multi-cancer screening, reshape diagnostic pathways, and offer cheaper, simpler surveillance—assuming the usual caveats about follow-up testing and false positives.
- Frontline: ctDNA and cfDNA - monitoring, screening, and reliability questions (4)
- On location: early-detection debates, AI risk stratification and screening value (4)
- On the ground: UCLA’s inexpensive blood test expands multi-disease detection (4)
- All Other Stories
Frontline: ctDNA and cfDNA - monitoring, screening, and reliability questions
On location: early-detection debates, AI risk stratification and screening value
On the ground: UCLA’s inexpensive blood test expands multi-disease detection
All Other Stories
Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs
Kyle LaHucik / endpoints - In its third acquisition of 2026, Gilead is spending $3.15 billion upfront to snag a next-generation antibody-drug conjugate platform from German startup Tubulis. The California biopharma could pay out another $1.85 billion down the road ...
AI Summary: Gilead Sciences struck a multibillion-dollar acquisition to add Tubulis and bolster its oncology pipeline, buying into antibody-drug conjugate technology. The deal signals Gilead’s strategic pivot to expand beyond infectious disease into cancer therapeutics, accelerating access to novel modalities and reshaping competitive dynamics in biopharma.
Common metabolic enzyme could predict cancer immunotherapy benefits—and help more patients respond
medicalxpress - Immunotherapies have transformed cancer treatment by helping the immune system recognize and attack tumors. They work for only about 20% of patients, though, and doctors still struggle to predict who will benefit.
AI Summary: New research identifies a common metabolic enzyme as a potential biomarker predicting benefit from cancer immunotherapy, and investigators propose that controlling intracellular metabolite routing could enhance responses. Together, these findings suggest metabolic pathways are both useful predictors and actionable targets to convert non‑responders into responders.
- Metabolic signals predict and boost immunotherapy responses (5)
- Other related research and expert commentary (8)
- Scaling CAR‑T: access, effects, and biomarker collaborations (3)
- Unmasking tumors: epigenetic and immune reprogramming strategies (4)
- All Other Stories
Metabolic signals predict and boost immunotherapy responses
Other related research and expert commentary
Scaling CAR‑T: access, effects, and biomarker collaborations
Unmasking tumors: epigenetic and immune reprogramming strategies
All Other Stories
Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline
esmo - This ESMO–EURACAN CPG provides key recommendations for the diagnosis, staging, treatment and follow-up for uveal melanoma. It includes percutaneous hepatic perfusion and tebentafusp as treatment options for metastatic disease, reflecting emerging evidence…
AI Summary: ESMO–EURACAN released a comprehensive clinical practice guideline for uveal melanoma covering diagnosis, staging, surveillance and systemic management. The guidance clarifies best practices for multidisciplinary care, risk stratification and therapeutic sequencing, aiming to standardize treatment and follow‑up for a rare but high‑risk ocular tumour.
Bowelbabe Fund celebrates raising £20m by announcing the Bowelbabe Vaccine
Sophie Wedekind / cancerresearchuk - The Bowelbabe Fund has raised more that £20 million and has announced the next wave of funded projects, including the Bowelbabe Vaccine.The post Bowelbabe Fund celebrates raising £20m by announcing the Bowelbabe Vaccine appeared first on Cancer Research U…
AI Summary: The Bowelbabe Fund celebrated a £20 million fundraising milestone and unveiled plans for a Bowelbabe Vaccine initiative, drawing high‑profile support. Organizers framed the cash infusion as a catalyst for prevention and research efforts, while public endorsements highlighted momentum — and the fundraising thermometer that finally stopped making them blush.
Targeted, High-dose Radiation May Improve Treatment for ‘Supermassive’ Bile Duct Tumors
Kathleen Medora / aacr - Patients with very large intrahepatic cholangiocarcinoma experienced improved outcomes when targeted, high-dose radiation was added to chemotherapy PHILADELPHIA – Patients with supermassive intrahepatic cholangiocarcinoma (ICC) benefited from ablative rad…
AI Summary: New clinical reports indicate that targeted high‑dose radiation can improve outcomes for very large “supermassive” bile duct tumors, offering better local control and symptom relief than conventional approaches. Early data suggest this intensity‑modulated strategy may expand options for otherwise difficult‑to‑treat cases, though longer follow‑up is needed to confirm survival benefits.
Phase 3 ATOMIC trial Updates: Atezolizumab plus FOLFOX for Stage III dMMR Colon Cancer
oncodaily - Patients with stage III colon cancer are typically treated with surgical resection followed by adjuvant chemotherapy with a fluoropyrimidine-plus-oxaliplatin regimen. However, approximately 30% of patients with stage III disease experience […]
AI Summary: Phase 3 ATOMIC updates show that adding atezolizumab to FOLFOX/mFOLFOX6 improves disease‑free survival in patients with Stage III dMMR colon cancer, with a substantial reduction in recurrence risk reported. The results suggest immunotherapy may become integral to adjuvant treatment for this biomarker‑defined subgroup.
- ATOMIC breakthrough: atezolizumab reduces recurrence in dMMR colon patients (3)
- From the wards: MSI-H immunotherapy expands beyond colon (3)
- On the frontline: colorectal biomarkers and therapy innovations (6)
- Other headlines: cancer research news outside ATOMIC focus (1)
- All Other Stories
ATOMIC breakthrough: atezolizumab reduces recurrence in dMMR colon patients
From the wards: MSI-H immunotherapy expands beyond colon
On the frontline: colorectal biomarkers and therapy innovations
Other headlines: cancer research news outside ATOMIC focus
All Other Stories
NorthStar Trial Analysis at ELCC 2026: Local Consolidative Therapy in EGFR-Mutant NSCLC
oncodaily - The management of metastatic EGFR-mutant non-small cell lung cancer (NSCLC) has been transformed by the introduction of third-generation EGFR tyrosine kinase inhibitors, particularly osimertinib. While systemic therapy achieves meaningful disease […]
AI Summary: ELCC 2026 brought together clinicians and investigators to present pivotal lung‑cancer studies, including localized consolidative therapy, SBRT sequencing with immunotherapy, and trials addressing under‑represented KRAS and EGFR populations. The conference highlighted survival and tumor‑control signals, networked international collaborators, and emphasized real‑world applicability — proving once again that conferences are where hope meets peer review.
- At ELCC: late‑breaking trials reshaping clinical practice (6)
- OTHER: misc lung oncology studies, regulatory and surgical updates (8)
- Precision push: molecular testing, KRAS degraders, ADC collaborations advancing care (6)
- Voices from ELCC: clinicians share breakthroughs and practical takeaways (17)
- All Other Stories
At ELCC: late‑breaking trials reshaping clinical practice
OTHER: misc lung oncology studies, regulatory and surgical updates
Precision push: molecular testing, KRAS degraders, ADC collaborations advancing care
Voices from ELCC: clinicians share breakthroughs and practical takeaways
All Other Stories
Spatial mapping technique allows researchers to understand tumor architecture
medicalxpress - Tumors contain many different types of cells organized in complex spatial patterns that can influence how the disease progresses. Because of this, it is hard to predict how a tumor will develop and respond to treatment. Researchers at the University of Il…
AI Summary: Advanced spatial mapping techniques revealed how tumor architecture and local microenvironments reorganize — including changes driven by tumor‑linked viruses — altering immune cell positioning and signaling. The work provides a high‑resolution blueprint for understanding treatment resistance and suggests new targets for precision therapies that consider the tumor’s geographic biology, not just its genetics.
- Field report: Immune geography dictates therapy response and resistance (4)
- On scene: microbes and viruses remap tumor microenvironments (3)
- On the ground: spatial multi-omics maps tumor architecture (4)
- Other: Miscellaneous tumor biology, therapies, biomarkers (18)
- All Other Stories
Field report: Immune geography dictates therapy response and resistance
On scene: microbes and viruses remap tumor microenvironments
On the ground: spatial multi-omics maps tumor architecture
Other: Miscellaneous tumor biology, therapies, biomarkers
All Other Stories
AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trial
Lei Lei Wu / endpoints - New clinical trial data on the in vivo CAR-T therapy that AstraZeneca acquired last year suggest that while the experimental treatment can curb multiple myeloma in some patients, it may not be safer than the ...
AI Summary: Early reports from a phase 1 in‑vivo CAR‑T program show promising anti‑myeloma activity following direct in‑body CAR induction targeting BCMA, but investigators also reported a treatment‑related death in a China trial. The mixed signals underscore the potential of in‑vivo CAR approaches while spotlighting safety, dosing and monitoring challenges that must be resolved before wider adoption.
- AstraZeneca's in‑vivo CAR‑T: early wins, serious safety questions (4)
- Myeloma community reacts: experts, conferences and paper highlights (7)
- Next‑gen T‑cell strategies and regulatory hurdles (4)
- All Other Stories
AstraZeneca's in‑vivo CAR‑T: early wins, serious safety questions
Myeloma community reacts: experts, conferences and paper highlights
Next‑gen T‑cell strategies and regulatory hurdles
All Other Stories
EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib
esmo - It is intended for the treatment of paediatric patients with low-grade glioma with BRAF alterations whose disease has progressed after one or more prior systemic therapies
AI Summary: Five‑year results from KEYNOTE‑671 indicate perioperative pembrolizumab yields sustained clinical benefit in early‑stage non‑small‑cell lung cancer, improving outcomes even when pathological complete response is not achieved. The data bolster the case for integrating immune checkpoint blockade into surgical-era treatment strategies, shifting conversations about neoadjuvant and adjuvant sequencing.
- Frontline precision: KRAS G12D and EGFR targeted advances in NSCLC (4)
- Insider view: evolving IO biology, toxicity and access debates (3)
- On-the-ground: Neoadjuvant immunotherapy and radiotherapy reshaping lung surgery (4)
- OTHER: assorted oncology updates outside perioperative NSCLC focus (4)
- All Other Stories
Frontline precision: KRAS G12D and EGFR targeted advances in NSCLC
Insider view: evolving IO biology, toxicity and access debates
On-the-ground: Neoadjuvant immunotherapy and radiotherapy reshaping lung surgery
OTHER: assorted oncology updates outside perioperative NSCLC focus
All Other Stories
J. Michael Bishop, Nobel Prize Winner for Cancer Research, Dies at 90
Delthia Ricks / nytimes - He helped discover cancer-causing genes. Later, as chancellor of the University of California, San Francisco, he led a major expansion.
AI Summary: J. Michael Bishop, Nobel Prize–winning cancer researcher, has died at 90. Colleagues recall his transformative work illuminating oncogenes and reshaping cancer biology, plus a career of mentorship that seeded generations of scientists. The obituaries and memorial pieces celebrate both his landmark discoveries and the enduring institutions and researchers he helped build.
Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia
esmo - Findings from the RECITE study
AI Summary: A clinical study found romiplostim effective in treating and preventing recurrent persistent chemotherapy‑induced thrombocytopenia, restoring platelet counts and enabling continuation of scheduled cytotoxic therapy. Patients experienced fewer delays and dose reductions, positioning romiplostim as a useful strategy to keep chemo on track—because, apparently, platelet math still runs cancer care.
Results from the Phase 2 POLAR Trial: Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer
oncodaily - Pancreatic cancer remains one of the most challenging malignancies to treat, particularly in the metastatic setting, where immunotherapy has historically shown minimal activity. However, a biologically defined subset of patients […]
AI Summary: The Phase 2 POLAR trial presented results evaluating pembrolizumab combined with olaparib in homologous recombination–deficient metastatic pancreatic cancer, including safety, response rates and biomarker analyses. Investigators observed signals of activity in HRD‑selected patients, suggesting the immunotherapy–PARP inhibitor combination merits larger randomized testing rather than immediate headline glory.
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong
abcnews - Federal health officials have issued a warning about controversial statements made by biotech billionaire Dr. Patrick Soon-Shiong about one of his company's cancer drugs
AI Summary: The FDA issued warnings over promotional materials and public statements related to a cancer drug associated with a biotech entrepreneur, finding claims that could mislead patients and investors. The agency asked the company to correct materials and refrain from unsubstantiated efficacy or safety assertions while oversight and compliance reviews continue.
Merck’s $6.7B Terns Acquisition Positions It to Challenge a Blockbuster Novartis Cancer Drug
Frank Vinluan / medcitynews - Merck has been acquiring assets that could help make up for the coming revenue decline as its top product, the cancer drug Keytruda, drops off the patent cliff. Terns Pharmaceuticals’ lead product candidate, in development for treating a type of leukemia,…
AI Summary: Merck announced a definitive deal to acquire Terns Pharmaceuticals for about $6.7 billion, gaining a promising leukemia drug candidate and bolstering its oncology pipeline. The transaction aims to combine Merck’s late‑stage development and commercialization capabilities with Terns’ targeted therapy assets to compete in hematologic malignancies.
Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows
medicalxpress - New evidence from a Chinese cohort presented at the European Lung Cancer Congress (ELCC) 2026 shows that one-time low-dose computed tomography (LDCT) screening can significantly reduce lung cancer mortality in a non–risk based population, including indivi…
AI Summary: A large population‑based study found organized lung cancer screening reduced mortality even in people who never smoked, demonstrating the benefits of expanded CT screening criteria and systematic outreach. The results suggest screening programs can detect lethal disease earlier across broader risk groups, prompting reconsideration of current eligibility rules.
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Ayisha Sharma / endpoints - Novartis has budgeted $2 billion upfront to buy a more selective PI3Kα inhibitor for breast cancer. The Swiss pharma already has Piqray with a similar target, but drugmakers are now entering the next-generation era as ...
AI Summary: Novartis agreed to pay $2 billion upfront to acquire Synnovation’s mutant‑selective PI3Kα inhibitor, a bet to revive and strengthen PI3K‑targeting combination strategies in breast cancer. The deal swaps in external innovation for internal development speed, shoring up the company’s oncology pipeline while quietly admitting buying is sometimes faster than building.
Innovative research captures emotional and social realities of denture wearers
medicalxpress - Researchers at the University of Sheffield have developed a new patient-focused tool designed to better understand the lived experience of people wearing removable partial dentures. In their study published in the journal Gerodontology, the researchers in…
AI Summary: An international ACT for Children delegation visited Yerevan to support Armenia’s pediatric oncology services through training, resource sharing, and collaborative program development. The visit focused on strengthening local clinical capacity, improving access to treatments, and forging partnerships to advance childhood cancer care—practical help rather than platitudes, with an eye on sustainable improvements.
- Global systems and communication: policy, partnerships, and cultural context (3)
- OTHER: Unrelated health research (denture study) (1)
- Survivorship care: long-term needs, nursing, and AI solutions (3)
- Yerevan visit: ACT for Children strengthens local pediatric oncology care (3)
- All Other Stories